Zentalis Pharmaceuticals, Inc. (ZNTL) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2025-12-31..
Gross margin
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2025-12-31 | (m) | $0.00 | (m) | (m) |
| 2025-09-30 | (m) | $26.86M | (m) | (m) |
| 2025-06-30 | (m) | $26.86M | (m) | (m) |
| 2025-03-31 | (m) | $26.86M | (m) | (m) |
| 2024-12-31 | (m) | $67.42M | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $0.00 | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |